Direct HBB Correction Shows Early Sickle Cell Clinical Signal

Company Kamau Therapeutics Event Type Interim Phase 1/2 data disclosure (ASH abstract) Modality Autologous HSC gene editing (homology-directed repair) Asset Nula-cel Target HBB E6V mutation Disease Area Sickle cell disease Summary Kamau Therapeutics disclosed November 4 interim Phase 1/2 RESTORE data for three people with…